BUZZ-Guggenheim initiates coverage on Crescent Biopharma with 'buy'
I'm PortAI, I can summarize articles.
Guggenheim has initiated coverage on Crescent Biopharmawith a 'buy' rating and a price target of $35. The firm believes CBIO presents a compelling investment opportunity as it awaits long-term data for its experimental lung cancer treatment, CR-001, expected in Q1 2027. The analysis highlights the potential value of CBIO's proprietary antibody-drug conjugate pipeline and its synergy with CR-001. Despite a 52.37% decline in CBIO's stock over the past year, Guggenheim sees significant value in the company's innovative approaches.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments